{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:19:24Z","timestamp":1760833164734,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.bmcl.2023.129374","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T21:18:18Z","timestamp":1686604698000},"page":"129374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Synthesis, activity, metabolic stability and cell permeability of new cytosolic phospholipase A2\u03b1 inhibitors with 1-indolyl-3-phenoxypropan-2-one structure"],"prefix":"10.1016","volume":"92","author":[{"given":"Angelina","family":"Subeska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merlin Ekodo","family":"Voundi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walburga","family":"Hanekamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Mulac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1645-7913","authenticated-orcid":false,"given":"Matthias","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2023.129374_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1471-4159.1990.tb08813.x","article-title":"Arachidonic acid cascade and signal transduction","volume":"55","author":"Shimizu","year":"1990","journal-title":"J Neurochem"},{"key":"10.1016\/j.bmcl.2023.129374_b0010","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.2174\/0929867325666180117103919","article-title":"Targeting cytosolic phospholipase A2\u03b1 for novel anti-iInflammatory agents","volume":"25","author":"Soubhye","year":"2018","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmcl.2023.129374_b0015","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/17460441.2021.1942835","article-title":"The design and discovery of phospholipase A2 inhibitors for the treatment of inflammatory diseases","volume":"16","author":"Batsika","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.bmcl.2023.129374_b0020","series-title":"Anti-Inflammatory Drug Discovery (RSC Drug Discovery Series No. 26)","first-page":"35","article-title":"Inhibitors of cytosolic phospholipase A2\u03b1 as anti-inflammatory drugs","author":"Lehr","year":"2012"},{"key":"10.1016\/j.bmcl.2023.129374_b0025","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1021\/jm701467e","article-title":"Indole cytosolic phospholipase A2\u03b1 inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib","volume":"51","author":"McKew","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129374_b0030","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1021\/jm011050x","article-title":"Design and synthesis of a novel and potent series of inhibitors of cytosolic phospholipase A2 based on a 1,3-disubstituted propan-2-one skeleton","volume":"45","author":"Connolly","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129374_b0035","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1021\/jm1001088","article-title":"1-(5-Carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A2\u03b1 with reduced lipophilicity: synthesis, biological activity, metabolic stability, solubility, bioavailability, and topical in vivo activity","volume":"53","author":"Drews","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129374_b0040","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cbi.2013.10.005","article-title":"Investigations on the metabolic stability of cytosolic phospholipase A2\u03b1 inhibitors with 1-indolylpropan-2-one structure","author":"Fabian","year":"2013","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.bmcl.2023.129374_b0045","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/bdd.1946","article-title":"Involvement of microsomal NADPH-cytochrome P450 reductase in metabolic reduction of drug ketones","volume":"36","author":"Lehr","year":"2015","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.bmcl.2023.129374_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117110","article-title":"Synthesis and pharmacokinetic properties of novel cPLA2\u03b1 inhibitors with 1-(carboxyalkylpyrrolyl)-3-aryloxypropan-2-one structure","volume":"77","author":"Subeska","year":"2023","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2023.129374_b0055","unstructured":"Banville J, Remillard R, Balasubramanian N, Bouthillier G, Martel A. Alpha-amino, -thio, -oxo substituted ketones as phospholipase inhibitors. US2002037875, 2002."},{"key":"10.1016\/j.bmcl.2023.129374_b0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jchromb.2012.05.018","article-title":"Determination of arachidonic acid by on-line solid-phase extraction HPLC with UV detection for screening of cytosolic phospholipase A2\u03b1 inhibitors","volume":"900","author":"Hanekamp","year":"2012","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.bmcl.2023.129374_b0065","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ejmech.2016.10.039","article-title":"Structure-activity relationship studies on 1-(2-oxopropyl)indole-5-carboxylic acids acting as inhibitors of cytosolic phospholipase A2\u03b1: Effect of substituents at the indole 3-position on activity, solubility, and metabolic stability","volume":"125","author":"Arnsmann","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129374_b0070","unstructured":"OECD Guidelines for the Testing of Chemicals No. 117 e Partition Coefficient (n-octanol\/water, High Performance Liquid Chromatography (HPLC) Method, 2004."},{"key":"10.1016\/j.bmcl.2023.129374_b0075","doi-asserted-by":"crossref","unstructured":"Barth M, Rudolph S, Kampschulze J, et al. Hexafluoroisopropyl carbamates as selective MAGL and dual MAGL\/FAAH inhibitors: biochemical and physicochemical properties. ChemMedChem. 2022;17: e202100757. https:\/\/doi.org\/10.1002\/cmdc.202100757.","DOI":"10.1002\/cmdc.202100757"},{"key":"10.1016\/j.bmcl.2023.129374_b0080","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1023\/A:1011930411574","article-title":"Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds","volume":"15","author":"Yazdanian","year":"1998","journal-title":"Pharm Res"},{"key":"10.1016\/j.bmcl.2023.129374_b0085","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/jps.23069","article-title":"Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2","volume":"10","author":"Mease","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.bmcl.2023.129374_b0090","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2133.2011.10637.x","article-title":"Inhibition of benzalkonium chloride-induced skin inflammation in mice by an indol-1-ylpropan-2-one inhibitor of cytosolic phospholipase A2\u03b1","volume":"166","author":"Roebrock","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bmcl.2023.129374_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112786","article-title":"Contribution of cyclooxygenase-1-dependent prostacyclin synthesis to bradykinin-induced dermal extravasation","volume":"148","author":"Krybus","year":"2022","journal-title":"Biomed Pharmacother"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23002524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23002524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:48:11Z","timestamp":1760773691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X23002524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":19,"alternative-id":["S0960894X23002524"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129374","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, activity, metabolic stability and cell permeability of new cytosolic phospholipase A2\u03b1 inhibitors with 1-indolyl-3-phenoxypropan-2-one structure","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129374"}}